Search company, investor...

Compare Arctoris vs Recursion

Customers evaluate the quality of Arctoris's products using the following success metrics.


Arctoris Logo

Arctoris is 8 yrs old and is based in United Kingdom.

Arctoris develops an automated drug discovery company. It combines its unique automation platform, Ulysses, with advanced machine learning approaches and a team of seasoned drug hunters to guide and progress drug discovery programs in oncology and neurology. It offers on-demand access to various drug discovery assays conducted by robotics to biotech companies, pharmaceutical corporations, and academic centers. It was founded in 2016 and is based in Oxfordshire, United Kingdom.

Recursion Logo

Recursion is 11 yrs old and is based in United States.

Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.

Founded Year


United Kingdom
United States

Demo Video

Arctoris did not submit their demo in their Analyst Briefing

Work for Arctoris?

Demo not available because Recursion has not claimed their profile.

Work for Recursion? Show off your product.


Martin-Immanuel Bittner (Founder, Chief Executive Officer)

See all 2 people

Blake Borgeson (Founder)

See all 5 people


Recursion last raised $50M on 7/13/2023.


Incubator/Accelerator - III
Corporate Minority - P2P - II

Total Raised



Tech Nation Upscale, Tech Nation Applied AI

See all 5 investors

NVIDIA, Baillie Gifford & Co.

See all 5 investors


Why Arctoris beats Recursion

    Information not available because Recursion has not claimed their profile.

    Work for Recursion? Claim your profile by submitting an Analyst Briefing. By submitting you can

    Show your primary competitive advantage
    Highlight your competitive differentiation
    Show why customers evalute your products
    Explain why customers choose your products and services

    Work for Recursion?

    Claim your profile now.


    • data quality
    • speed of data generation


    • Research services

      Biotech and pharma companies use our technology platform and expert team to progress their R&D better and faster.

    See all products


    Arctoris did not submit their products in their Analyst Briefing

    Work for Arctoris?

    Known Partners

    Arctoris did not submit their partners in their Analyst Briefing

    Work for Arctoris?

    Why They Buy

    Arctoris did not submit their references in their Analyst Briefing

    Work for Arctoris?

    News & Analysis

    Arctoris has been mentioned in our research 1 time.

    Recursion has been mentioned in our research 8 times.

    Expert Collections


    Artificial Intelligence

    10,944 items

    Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.


    Digital Health

    10,565 items

    The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


    AI 100

    299 items

    Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.


    Conference Exhibitors

    5,501 items

    HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare


    ESP Rankings position vendors based on their resources and execution.

    Arctoris is a Leader in AI oncology drug development

    AI oncology drug development

    The AI oncology drug development market leverages artificial intelligence and machine learning techniques to analyze vast amounts of genomic, proteomic, and clinical data, enabling more precise identification of therapeutic targets, prediction of drug responses, and optimization of treatment regimens. AI solutions in oncology drug development help researchers accelerate the discovery of novel compounds, design more effective clinical trials, and improve patient stratification for personalized medicine. By harnessing the power of AI, this market aims to enhance the efficiency and success rate of drug discovery and development, ultimately leading to the delivery of safer, more targeted, and potentially life-saving oncology treatments.

    Recursion has not been listed in an ESP Ranking.

    Work for Recursion? Brief our analysts to ensure your company gets considered.